wound healing   Optimizing Patient Outcomes

Peskin Pharmaceuticals® was founded to research, develop, and ultimately commercialize first-in-class therapeutics for circulatory system disorders and related cardiovascular complications; in particular, cardiovascular disease, diabetes, and cancer. Applying unique insights into the epigenetic pathways, our approach focuses on state-of-the-art research and development of plant-based lipids to solve circulatory problems that have grown more intractable and urgent in recent decades. The culmination of 2 decades in research in these areas led to significant advances in expediting surgical and wound healing.

Our methodology is unique. We focus on supporting and optimizing the patient's natural physiologic processes, not blocking or impeding metabolic pathways. The results are novel, highly effective treatment for specific chronic diseases / disorders across diverse patient populations.

There remains significant unmet need in wound healing with no effective drugs, particularly in diabetic patients. Peskin Pharmaceuticals® has developed a preclinical drug candidate, PSK003, that we believe has the potential to become the new first-in-class drug for healing diabetic foot ulcers (DFUs).



Novel lipids-based pharmacognosy solutions expediting surgical healing.

Contact Professor Peskin